14 th call for research projects within the ERA-NET JPIAMR-ACTION

1. 2. 2022

The DRUID Call aims to improve the treatment of bacterial and fungal infections (including coinfection) and/or the prevention of the emergence/spread of resistance in humans, animals or plants through the improvement of the efficacy, specificity, delivery, combinations and/or repurposing of drugs and plant protection agents.

Who can apply:

CZ: universities, public research institutes and/or another entities classified as research organisations.
(More specification in national rules of each participating country.)

Eligible countries: Belgium, Canada, Czech Republic, Denmark, Estonia, France, Germany, Hungary, Israel, Italy, Latvia, Lithuania, Moldova, Poland, Spain, Sweden, Switzerland, United Kingdom

Eligibility rules for the consortia are:

• The consortium must include a minimum of three (3) eligible partners asking for funding from three (3) different eligible countries (including at least two amongst EU Member States or Associated Countries).
• The consortium can include a maximum of six (6) project partners (including non-funded partners). The maximum number of partners can be increased to seven (7) if at least a partner from an under-represented country (including LMICs) or a company is included in the consortium.

Duration of the grant:

max. 3 years

Budget:

Each country will fund its own approved project partners.
CZ allocation: 500.000 €

The aid intensity for activities carried out by a research organisation might be at the level of 100 % (100 % for fundamental/basic research activities, 50 % for applied research activities and 25 % for experimental development activities)

Timetable:

Opening: 11. 1. 2022
Deadline (pre-proposals): 8. 3. 2022
Full proposal invitations: 30. 6. 2022
Deadline (full proposals): 5. 7. 2022
Publication of results: 18. 11. 2022

Topics of the call:

Your proposal should focus on licenced antimicrobial agents(antibiotics/antifungals) or agents under pre-clinical and/or early clinical development, and should address at least one of the following topics:

• Improvement of drug/plant protection agent efficacy and/or specificity through chemical modifications (including hit to lead optimisation);
• Drug/plant protection agent repurposing;
• Optimisation of drug/plant protection agent combinations, alone or with adjunct therapies (including therapeutic vaccines);
• Design and implementation of new strategies (including optimisation of drug doses) for improved application, efficacy and delivery of single or combinations of antimicrobials;
• Design and implementation of innovative tools, including novel chemistry and/or new materials for improved application, efficacy and delivery of antimicrobials.

Your proposal can include the development of new mathematical models, optimisation of antimicrobial combinations and/or conditions for clinical/agricultural use, or treatment protocols based on combination therapy, personalised medicine and PK/PD. Studies may include companion diagnostics in the optimisation of treatment strategies.

Type of studies/ experimental approaches:

• In silico, in vitro, in vivo and/or
• Preclinical and clinical studies in human and in all veterinary settings, and/or
• Studies in crop/plant settings, including field studies

Eligible costs:

• Personal costs
• Consumables
• Equipment
• Indirect costs

Oddělení projektové podpory nabízí možnost propagace expertízy pracovišť LF MU prostřednictvím vložení informací do portálu Crowdhelix ve vztahu k této nebo budoucím výzvám. Crowdhelix je platforma umožňující vytváření vazeb mezi výzkumnými pracovišti a inovativními společnostmi prostřednictvím zveřejnění nabídky/poptávky expertízy pro řešení společných mezinárodních projektů.

Kontaktní osoba pro LF MU